Posters

Evaluation of outcomes from transscleral cyclodiode laser, in a tertiary referral centre, including the outcomes in neovascular glaucoma in the era of anti-VEGF

Poster Details

First Author: S. whitlow IRELAND

Co Author(s):    N. Collins   A. Doyle                 

Abstract Details

Purpose:

To assess the outcomes from transscleral cyclodiode laser, in a tertiary referral centre, including the outcomes in neovascular glaucoma in the era of anti-VEGF

Setting:

Retrospective chart review of patients who underwent cyclodiode laser between May 2014 and Sept 2015 in a tertiary centre. 106 patients had undergone cyclodiode laser.

Methods:

59 patients (60 eyes) had sufficient follow-up data in the study. Data included: demographics including age, gender, type of glaucoma, prior glaucoma surgery or cyclodiode treatment and for neovascular glaucoma (NVG) whether the patient had prior treatment with PRP or anti-VEGF injection; cyclodiode laser parameters including total energy administered, concomitant anti-VEGF treatment and whether the patient was under the care of a glaucoma subspecialist (GC) or a consultant not specializing in glaucoma (NGC). Data was collected on the following variables for patients pre- and post-cyclodiode laser: intraocular pressure (IOP), best corrected visual acuity (BCVA) and number of glaucoma medications.

Results:

There was a significant reduction in mean IOP from 34.2mmHg (StDev 11.7mmHg) to 20.9mmHg (StDev 10.2mmHg) at 6 weeks post cyclodiode laser treatment (student paired t-test (2-tailed) p < 0.0001). 65% of patients achieved an IOP < 22mmHg or decreased IOP by at least 30%. 35% of patients were able to decrease the number of IOP lowering agents. 8 patients had undergone prior PRP or anti-VEGF treatment for NVG, and 5 patients had no prior treatment. Patients treated with prior PRP / anti-VEGF had lower pre- and post-cyclodiode IOP (mean IOP 33.9 and 18.5 respectively) than those without prior treatment (mean IOP 43.2 and 21.8mmHd respectively) although the differences were not statistically significant

Conclusions:

Cyclodiode laser is an effective way to decrease IOP and to decrease the number of IOP medications. This study did not show the any significant difference in the whether a Glaucoma or non glaucoma specialist preformed the procedure. This study suggests that patients who had NVG that were previously treated with prior PRP/Avastin had greater IOP decrease with cyclodiode laser than patients without prior PRP/Avastin. However a larger study would be required to have the result statistically significant.

Financial Disclosure:

NONE